Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly

Basit Öğe Kaydı
dc.authoridTuyji Tok, Yesim/0000-0003-4970-9216
dc.authoridHamuryudan, Vedat/0000-0001-6625-1652
dc.authoridbalkan, ilker inanc/0000-0002-8977-5931
dc.authoridOztas, Mert/0000-0002-4077-1374
dc.authoridDuru, Guzin/0000-0002-4774-9284
dc.authoridSeyahi, Emire/0000-0003-4965-2918
dc.authoridBakhdiyarli, Guldaran/0000-0002-2629-3345
dc.authorwosidKuskucu, Mert Ahmet/B-6373-2009
dc.authorwosidTuyji Tok, Yesim/AAM-8801-2020
dc.authorwosidHamuryudan, Vedat/AAA-1100-2020
dc.authorwosidbalkan, ilker inanc/AAI-1578-2019
dc.authorwosidSEYAHI, EMIRE/AAB-3576-2020
dc.authorwosidSalto?lu, Neşe/AAV-2262-2021
dc.authorwosidOztas, Mert/AAL-8782-2020
dc.contributor.authorSeyahi, Emire
dc.contributor.authorBakhdiyarli, Guldaran
dc.contributor.authorOztas, Mert
dc.contributor.authorKuskucu, Mert Ahmet
dc.contributor.authorTok, Yesim
dc.contributor.authorSut, Necdet
dc.contributor.authorOzcifci, Guzin
dc.date.accessioned2024-06-12T11:14:07Z
dc.date.available2024-06-12T11:14:07Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective To assess antibody response to inactivated COVID-19 vaccine in patients with immune-mediated diseases (IMD) among hospital workers and people aged 65 and older. Methods In this cross-sectional study, we studied 82 hospital workers with IMD (mean age: 42.2 +/- 10.0 years) and 300 (mean age: 41.7 +/- 9.9 years) controls. Among + 65 aged population, we studied 22 (mean age: 71.4 +/- 4.5 years) patients and 47 controls (mean age: 70.9 +/- 4.8 years). All study subjects had a negative history for COVID-19. Sera were obtained after at least 21 days following the second vaccination. Anti-spike IgG antibody titers were measured quantitatively using a commercially available immunoassay method. Results Patients with IMD were significantly less likely to have detectable antibodies than healthy controls both among the hospital workers (92.7% vs 99.7%, p < 0.001) and elderly population (77.3% vs 97.9%, p = 0.011). Among patients with IMD, those using immunosuppressive or immune-modulating drugs (64/75, 85.3%) were significantly less likely to have detectable antibodies compared to those off treatment (29/29, 100%) (p = 0.029). Additionally, a negative association between age and the antibody titer categories among patients (r = - 0.352; p < 0.001) and controls (r = - 0.258; p < 0.001) were demonstrated. Conclusions Among hospital workers, the vast majority of patients with IMD and immunocompetent controls developed a significant humoral response following the administration of the second dose of inactivated COVID-19 vaccine. This was also true for the elderly population, albeit with lower antibody titers. Immunosuppressive use, particularly rituximab significantly reduced antibody titers. Antibody titers were significantly lower among those aged >= 60 years both in patient and control populations. Whether these individuals should get a booster dose warrants further studies.en_US
dc.description.sponsorshipTurkish Rheumatology Society [26.03.2021/5]en_US
dc.description.sponsorshipThis study was supported by the Turkish Rheumatology Society (26.03.2021/5).en_US
dc.identifier.doi10.1007/s00296-021-04910-7
dc.identifier.endpage1440en_US
dc.identifier.issn0172-8172
dc.identifier.issn1437-160X
dc.identifier.issue8en_US
dc.identifier.pmid34109466en_US
dc.identifier.scopus2-s2.0-85107492084en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1429en_US
dc.identifier.urihttps://doi.org/10.1007/s00296-021-04910-7
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23792
dc.identifier.volume41en_US
dc.identifier.wosWOS:000659408100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofRheumatology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSeroprevalenceen_US
dc.subjectAntibody To S1 Spike Proteinen_US
dc.subjectVaccinationen_US
dc.subjectCoronavacen_US
dc.subjectCOVID-19en_US
dc.subjectInflammatory Diseasesen_US
dc.subjectHospital Workersen_US
dc.subjectElderlyen_US
dc.subjectHepatitis-Ben_US
dc.subjectSafetyen_US
dc.subjectImmunogenicityen_US
dc.subjectEfficacyen_US
dc.subjectTrialen_US
dc.titleAntibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderlyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu